Replies to post #185323 on Biotech Values

[poorgradstudent]

Re: TRVN

The management team strikes me as singularly unimpressive

Could be. You're really buying this one for the advisory board: a Nobel Laureate and a highly productive mentee.

[iwfal]

TRVN ACRX

The management team strikes me as singularly unimprssive.

Curious what makes you say that? Truly. They have made reasonable decisions so far wrt the IV pain medication. A little spinny (e.g. The recent change in direction wrt therapeutic index) when it comes to data presentation, but on the whole ok. (AHF OTOH is different, but that is partnered and probably not either a distraction or much cash burn)

And they burn through cash like crazy.

Can't dispute that. But they also get their trials done quickly. I am ok with that trade.

All told, I think their approach to the IV pain med is reasonable. Just not clear the drug is enough better to take enough market. To thread the needle and show both better safety and better pain benefit.
(Note that there is a balance between drug better-ness and management capability. With with a stellar drug you can get away with a mediocre management, and vice versa.)

I think ACRX looks better, if you want a post-operative pain company.

Why is sublingual a solution to much? (Not meant to be a ding, but truly that isn't obvious to me)